Citi Upgrades Ultragenyx Pharma (RARE) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts RARE Hot Sheet
Price: $16.10 -4.05%
Rating Summary:
13 Buy, 13 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Rating Summary:
13 Buy, 13 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Join SI Premium – FREE
Citi analyst Yigal Nochomovitz upgraded Ultragenyx Pharma (NASDAQ: RARE) from Sell to Neutral with a price target of $54.00 (from $46.00).
For an analyst ratings summary and ratings history on Ultragenyx Pharma click here. For more ratings news on Ultragenyx Pharma click here.
Shares of Ultragenyx Pharma closed at $53.61 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Norwegian Cruise (NCLH) PT Raised to $22 at Freedom Broker, Upgrades to Buy
- Stryker (SYK) PT Lowered to $325 at Piper Sandler
- Regeneron Pharma (REGN) PT Raised to $875 at Baird
Create E-mail Alert Related Categories
Analyst PT Change, UpgradesRelated Entities
CitiSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
